Monitoring Longeveron Inc (LGVN) after recent insider movements
Longeveron Inc’s recent filing unveils that its Chief Scientific Officer Hare Joshua acquired Company’s shares for reported $100000.0 on Apr 11 ’24. In the deal valued at $2.35 per share,42,553 shares were bought. As a result of this transaction, Hare Joshua now holds 633,280 shares worth roughly $1.86 million. Then, Soffer Rock bought 31,915 shares, […]
Longeveron Inc’s latest rating changes from various analysts
Longeveron Inc’s recently made public that its Director Ross Cathy acquired Company’s shares for reported $6544.0 on Jan 10 ’24. In the deal valued at $1.31 per share,5,000 shares were bought. As a result of this transaction, Ross Cathy now holds 10,000 shares worth roughly $22000.0. Then, Baluch Khoso bought 8,322 shares, generating $11,915 in […]
Understanding the Risks of Investing in Longeveron Inc (LGVN)
Longeveron Inc’s recent filing unveils that its Director Ross Cathy acquired Company’s shares for reported $6544.0 on Jan 10 ’24. In the deal valued at $1.31 per share,5,000 shares were bought. As a result of this transaction, Ross Cathy now holds 10,000 shares worth roughly $3400.0000000000005. Then, Baluch Khoso bought 8,322 shares, generating $11,915 in […]
Longeveron Inc. (LGVN) stock sky rocketed during after-hours. Here’s to why?
Longeveron Inc. (NASDAQ: LGVN) stock gained by 135.27% at last close however its hiked by 50.95% in the after-hours trading session, as well. Longeveron is a clinical-stage biotechnology business focused on creating cellular therapeutics for age-related and life-threatening diseases. LGVN stock’ Significant Update The FDA has given Lomecel-B RPD designation for the cure of Hypoplastic […]
